Advertisement

Topics

Search Results for "Dcis Recurrence After Mastectomy"

00:16 EST 21st February 2017 | BioPortfolio

Matching Channels

Tumor recurrence

Oncotrace

For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual ...

WolffParkinsonWhite WPW syndrome

Wolff–Parkinson–White syndrome (WPW) is a syndrome of pre-excitation of ventricles of the heart due to an accessory pathway known as the bundle of Kent. This accessory pathway is an abno...

UroGenRA - Genitourinary cancer array

UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It...

Tumor markers

Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in t...

Matching News

Radiation Boost Reduces Local Recurrence in DCIS Patients

A study presented last month at ASTRO found that a boost of radiation therapy following lumpectomy in DCIS patients resulted in reduced rates of local recurrence.

Local Recurrence Less Likely With Mastectomy in Younger Breast Cancer Patients

Over the long term, local recurrence is more likely in young women with invasive breast cancer who undergo breast conserving surgery compared with those who undergo mastectomy, though survival is no d...

Radiation boost reduces local tumor recurrence for DCIS patients following WBRT

A supplemental "boost" of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whol...

Presence of DCIS, Younger Age Affect Breast Cancer Recurrence Risk

The presence of DCIS adjacent to invasive breast tumor and a younger age at diagnosis are associated with increased risk of ipsilateral breast tumor recurrence.

ASTRO 2016: Radiation boost reduces local tumour recurrence for DCIS patients following WBRT

A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive ...

High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study

We aimed to evaluate the influence of mammographic breast density at diagnosis on the risk of cancer recurrence and survival outcomes in patients with invasive breast cancer after modified radical mas...

Benefit of Radiation Boost in DCIS Validated (CME/CE)

(MedPage Today) -- Small but significant increase in recurrence-free survival

Radiation boost provides added benefit to DCIS patients following breast-conserving surgery and WBRT

A supplemental "boost" of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with Ductal Carcinoma In Situ (DCIS) who receive whol...

Matching PubMed Articles

Controversies in the Treatment of Ductal Carcinoma in Situ.

Ductal carcinoma in situ (DCIS) accounts for 20% of all newly diagnosed breast cancers. Mastectomy was once the gold standard for the treatment of DCIS; however, breast-conserving surgery (BCS) has be...

Is Sentinel Lymph Node Dissection Necessary in All Patients with Ductal Carcinoma In Situ Undergoing Total Mastectomy?

When ductal carcinoma in situ (DCIS) is found on core needle biopsy, rates of upgrade to invasive cancer of 25 per cent and nodal positivity of 10 per cent have been reported. Sentinel lymph node diss...

The Relationships between HER2 Overexpression and DCIS Characteristics.

The aim of this study was to demonstrate the correlation between human epidermal growth factor receptor 2 (HER2) overexpression and some poor prognosis factors in patients affected by ductal carcinoma...

Benefit of low dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.

Low-dose tamoxifen has comparable antiproliferative effect to the standard dose of 20 mg/day in biomarker trials, but its clinical efficacy remains unclear. We assessed the effect of low-dose tamoxife...

Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery.

Local recurrence is a major concern in patients who have undergone surgery for ductal carcinoma in situ (DCIS). The present study assessed whether the expression levels of hormone receptors, human epi...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement